Ask AI
Beyond A1C in T2D TM 2

CE / CME

Looking Beyond A1C in T2D Care: Incretin-Based Therapy for Cardiometabolic Risk Reduction

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: August 10, 2026

Expiration: August 09, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-S314.
  2. Writing Committee Members, Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;[Epub ahead of print].
  3. Zarei M, Sahebi Vaighan N, Farjoo MH, et al. Incretin-based therapy: a new horizon in diabetes management. J Diabetes Metab Disord. 2024;23:1665-1686.
  4. American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(suppl 1):S183-S215.
  5. Dulaglutide [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  6. Liraglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; 2025.
  7. Semaglutide (Ozempic) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; 2026.
  8. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515.
  9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130.
  10. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409-2420.
  11. Tirzepatide (Mounjaro) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  12. Tirzepatide (Zepbound) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  13. Semaglutide (Rybelsus/Ozempic tablets) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; 2026.
  14. Orforglipron [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  15. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-121.
  16. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145.
  17. Lixisenatide [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2026.
  18. Exenatide (Byetta) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2009.
  19. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.
  20. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239.
  21. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
  22. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
  23. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001-2012.
  24. Spiazzi BF, Zingano CP, Vest AR. Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2026;[Epub ahead of print].
  25. Semaglutide (Wegovy) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; 2026.